Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.

Leukemia - 1 Apr 2011

Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J, Kern W, Haferlach T

Abstract excerpt

The role of the nucleophosmin (NPM1) mutations in de novo acute myeloid leukemia (AML) is well analyzed, but the impact in secondary AML (s-AML) following myelodysplastic syndromes (MDS) or transformed myeloproliferative neoplasms (MPNs) remains unclear. We investigated 350 patients-283 s-AML after MDS and 67 transformed MPNs-for NPM1mut. NPM1mut was detected in 43/350 patients (12.3%) at diagnosis of s-AML...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blast Crisis
Share to Karyotyping
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Myeloproliferative Disorders

Share to Neoplasms, Second Primary

Share to Nucleophosmin

Share to Survival Rate

Source

Identifiers

PMID: 21233837
DOI: 10.1038/leu.2010.299

Genes

FLT3
NPM1
ETV6
PDGFRB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.PMID 21233837Read ↗

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.Semantic proximity Read ↗

NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?Semantic proximity Read ↗

NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.Semantic proximity Read ↗

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).Semantic proximity Read ↗

Progression in Myeloid Neoplasms: Beyond the Myeloblast.Semantic proximity Read ↗

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapySemantic proximity Read ↗

NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions.Semantic proximity Read ↗

NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?Semantic proximity Read ↗

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?Semantic proximity Read ↗

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.Semantic proximity Read ↗

Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.